Israeli - Kiingereza - Ministry of Health

tzamal bio-pharma ltd - methotrexate - solution for injection - methotrexate 50 mg/ml - methotrexate - methotrexate - psoriasis in adult patients :because of the high risk attending its use, methotrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. rheumatoid arthritis: methotrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well estabished according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose nsaids and usually a trial of at least one or more disease-modifying antirheumatic drugs.juvenile idiopathic arthritis:treatment of polyarthritic forms of severe, active juvenile idiopathic arthritis in patients 3 years of age and above when the response to non-steroidal anti-inflammatory drugs (nsaids) has been inadequatecrohn’s disease: mild to moderate crohn's disease either alone or in combination with corticosteroids in adult patients refractory or intolerant to thiopurines.

Armenia - Kiingereza - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

aspen bad oldesloe gmbh - trimethoprim, sulfamethoxazole - suspension - 8mg/ml+40mg/ml

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sulfasalazine, quantity: 500 mg - tablet, uncoated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; povidone; maize starch - ulcerative colitis and crohn's disease: adjunct in the treatment of ulcerative colitis with the usual supportive and dietary measures. for the management of severe, acute attacks of ulcerative colitis, rectal and systemic corticosteroid therapy appears to be clinically superior to sulfasalazine, but sulfasalazine may be more effective than corticosteroids in reducing the number of relapses in patients on maintenance therapy. in the treatment of active crohn's disease, especially in patients with colonic involvement. rheumatoid arthritis: salazopyrin en-tabs are indicated for rheumatoid arthritis which has failed to respond to non-steroidal anti-inflammatory drugs (nsaids).

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sulfasalazine, quantity: 500 mg - tablet, enteric coated - excipient ingredients: white beeswax; macrogol 20000; carnauba wax; magnesium stearate; povidone; cellacefate; maize starch; propylene glycol; colloidal anhydrous silica; glyceryl monostearate; purified talc - ulcerative colitis and crohn's disease: adjunct in the treatment of ulcerative colitis with the usual supportive and dietary measures. for the management of severe, acute attacks of ulcerative colitis, rectal and systemic corticosteroid therapy appears to be clinically superior to sulfasalazine, but sulfasalazine may be more effective than corticosteroids in reducing the number of relapses in patients on maintenance therapy. in the treatment of active crohn's disease, especially in patients with colonic involvement. rheumatoid arthritis: salazopyrin en-tabs are indicated for rheumatoid arthritis which has failed to respond to non-steroidal anti-inflammatory drugs (nsaids).

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

therakind (europe) limited - methotrexate - arthritis, psoriatic; precursor cell lymphoblastic leukemia-lymphoma; psoriasis; arthritis, rheumatoid; arthritis - antineoplastic agents - in rheumatological and dermatological diseasesactive rheumatoid arthritis in adult patients.polyarthritic forms of active, severe juvenile idiopathic arthritis (jia) in adolescents and children aged 3 years and over when the response to non-steroidal anti-inflammatory drugs (nsaids) has been inadequate.severe, treatment-refractory, disabling psoriasis which does not respond sufficiently to other forms of treatment such as phototherapy, psoralen and ultraviolet a radiation (puva) therapy and retinoids, and severe psoriatic arthritis in adult patients.in oncologymaintenance treatment of acute lymphoblastic leukaemia (all) in adults, adolescents and children aged 3 years and over.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sulfasalazine, quantity: 500 mg - tablet, enteric coated - excipient ingredients: white beeswax; propylene glycol; magnesium stearate; colloidal anhydrous silica; cellacefate; purified talc; macrogol 20000; povidone; carnauba wax; maize starch; glyceryl monostearate - ulcerative colitis and crohn's disease: adjunct in the treatment of ulcerative colitis with the usual supportive and dietary measures. for the management of severe, acute attacks of ulcerative colitis, rectal and systemic corticosteroid therapy appears to be clinically superior to sulfasalazine, but sulfasalazine may be more effective than corticosteroids in reducing the number of relapses in patients on maintenance therapy. in the treatment of active crohn's disease, especially in patients with colonic involvement. rheumatoid arthritis: pyralin en tablets are indicated for rheumatoid arthritis which has failed to respond to non-steroidal anti-inflammatory drugs (nsaids).

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

bridgewest perth pharma pty ltd - lidocaine hydrochloride monohydrate, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; sodium hydroxide; hydrochloric acid - lignocaine is indicated for the production of local or regional anaesthesia by nerve block, infiltration injection, caudal or other epidural blocks. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication or following resuscitation from cardiac arrest.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

bridgewest perth pharma pty ltd - lidocaine hydrochloride monohydrate, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; sodium hydroxide; hydrochloric acid - lignocaine is indicated for the production of local or regional anaesthesia by nerve block, infiltration injection, caudal or other epidural blocks. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication or following resuscitation from cardiac arrest.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

bridgewest perth pharma pty ltd - lidocaine hydrochloride monohydrate, quantity: 20 mg/ml - injection, solution - excipient ingredients: water for injections; sodium chloride - lignocaine is indicated for the production of local or regional anaesthesia by nerve block, infiltration injection, caudal or other epidural blocks. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication or following resuscitation from cardiac arrest.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

bridgewest perth pharma pty ltd - lidocaine hydrochloride monohydrate, quantity: 20 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - lignocaine is indicated for the production of local or regional anaesthesia by nerve block, infiltration injection, caudal or other epidural blocks. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication or following resuscitation from cardiac arrest.